GOG 3018: The OVAL Study: A Randomized, Controlled, Double-Arm, Open-Label, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Monotherpay for the Treatment of Recurrent Plantinum-Resistant Ovarian Canc
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Gynecologic Oncology Group
Start Date
January 30, 2019
End Date
November 30, 2022
Administered By
Duke Cancer Institute
Awarded By
Gynecologic Oncology Group
Start Date
January 30, 2019
End Date
November 30, 2022